Mr. Whalen joined Horizon Pharma in April 2010 and was named to his current position as senior vice president of business development and alliance management in March 2013. Mr. Whalen has more than 19 years of experience in the health care industry, leading and supporting transactions involving acquisitions, co-promotions, out licenses and strategic alliances. He led the out licenses of both LODOTRA® and DUEXIS® outside of the United States, supported Horizon’s IPO and other fund-raising activities and was involved in Horizon’s merger with Nitec (as a consultant).
Prior to Horizon, Mr. Whalen worked at Baxter Healthcare, where he led and supported a number of transactions as part of Baxter's Medication Delivery business, including a global collaboration with Halozyme for Hylenex® and a license and supply agreement with Wyeth for Zosyn®. Prior to Baxter, he worked at Searle, where he played a key role in the negotiation of the Celebrex® co-promotion agreement with Pfizer. His experience there encompassed various finance roles supporting business development, European operations, US marketing and R&D.
Mr. Whalen earned an MBA from the University of Illinois and a bachelor's degree in business administration from the University of Notre Dame.